

## DAFTAR PUSTAKA

1. Yogiandro M. Pendekatan klinis hipertensi. Dalam Buku Ajar Ilmu Penyakit Dalam. Ed keenam Jilid II. Editor oleh Setiati S, Alwi I, Sudoyo AW, Simadibrata KM, Setiyohadi B, Syam AF. Jakarta: Interna publishing. 2014:2259-83.
2. Shrestha PL, Shrestha PA, Vivo RP. Epidemiology of comorbidities in patients with hypertension. *Curr Opin Cardiol*. 2016;31(4):376–80.
3. Angeli F, Reboldi G, Verdecchia P. The 2014 hypertension guidelines: Implications for patients and practitioners in Asia. *Heart Asia*. 2015;7(2):21–5.
4. Muhadi. JNV 8: Evidence-based guideline penanganan pasien hipertensi Dewasa. *Cdk*. 2016;43(1):54–9.
5. The Seventh Report of the Joint National Committee on Prevention . Detection , evaluation , and treatment of High Blood Pressure. 2004;87: 1-5
6. Badan Penelitian dan Pengembangan Kesehatan. Riset Kesehatan Dasar (RISKESDAS) 2013. Lap Nas 2013. 2013:1–384.
7. Muntner P, Carey RM, Gidding S, Jones DW, Taler SJ, Wright JT, et al. Potential US population impact of the 2017 ACC/AHA high blood pressure guideline. *Circulation*. 2018;137(2):109–18.
8. Carey RM. The intrarenal renin-angiotensin system in hypertension. *Adv Chronic Kidney Dis*. 2015;22(3):204–10.
9. Kishore J, Gupta N, Kohli C, Kumar N. Prevalence of hypertension and determination of its risk factors in rural delhi. *Int J Hypertens*. 2016;1-6.
10. Moon JY. Recent update of renin-angiotensin-aldosterone system in the pathogenesis of hypertension. *Electrolyte Blood Press*. 2013;11(2):41–5.
11. Becari C, Oliveira EB, Salgado MCO. Alternative pathways for angiotensin II generation in the cardiovascular system. *Brazilian J Med Biol Res*. 2011;44(9):914–9.

12. Petrie MC, Padmanabhan N, McDonald JE, Hillier C, Connell JMC, McMurray JJV. Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease. *J Am Coll Cardiol*. 2001;37(4):1056–61.
13. Williams VR, Scholey JW. Angiotensin-converting enzyme 2 and renal disease. *Curr Opin Nephrol Hypertens*. 2018;27(1):35–41.
14. Te Riet L, Van Esch JHM, Roks AJM, Van Den Meiracker AH, Danser AHJ. Hypertension: renin-angiotensin-aldosterone system alterations. *Circ Res*. 2015;116(6):960–75.
15. Mizuno Y, Jacob RF, Mason RP. Effects of calcium channel and renin-angiotensin system blockade on intravascular and neurohormonal mechanisms of hypertensive vascular disease. *Am J Hypertens*. 2008;21(10):1076–85.
16. Danilczyk U, Penninger JM. Angiotensin-converting enzyme II in the heart and the kidney. *Circ Res*. 2006;98(4):463–71.
17. Roberts MA, Velkoska E, Ierino FL, Burrell LM. Angiotensin-converting enzyme 2 activity in patients with chronic kidney disease. *Nephrol Dial Transplant*. 2013;28(9):2287–94.
18. Battle D, Soler MJ, Wysocki J. New aspects of the renin-angiotensin system: angiotensin-converting enzyme 2 - a potential target for treatment of hypertension and diabetic nephropathy. *Curr Opin Nephrol Hypertens*. 2008;17(3):250–7.
19. Clarke NE, Turner AJ. Angiotensin-converting enzyme 2: The first decade. *Int J Hypertens*. 2012:1-12.
20. Imai Y, Kuba K, Ohto-Nakanishi T, Penninger JM. Angiotensin-converting enzyme 2 (ACE2) in disease pathogenesis. *Circ J*. 2010;74(3):405–10.
21. Chamsi-Pasha MAR, Shao Z, Tang WHW. Angiotensin-converting enzyme 2 as a therapeutic target for heart failure. *Curr Heart Fail Rep*. 2014;11(1):58–63.

22. Unger T, Paulis L, Sica DA. Therapeutic perspectives in hypertension: Novel means for renin angiotensin aldosterone system modulation and emerging device-based approaches. *Eur Heart J*. 2011;32(22):2739–47.
23. Koka V, Xiao RH, Chung ACK, Wang W, Truong LD, Lan HY. Angiotensin II up-regulates Angiotensin I-Converting Enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/p38 MAP kinase pathway. *Am J Pathol*. 2008;172(5):1174–83.
24. Niu W, Qi Y, Hou S, Zhou W, Qiu C. Correlation of angiotensin-converting enzyme 2 gene polymorphisms with stage 2 hypertension in Han Chinese. *Transl Res*. 2007;150(6):374–80.
25. Yang C-W, Lu L-C, Chang C-C, Cho C-C, Hsieh W-Y, Tsai C-H, et al. Imbalanced plasma ACE and ACE2 level in the uremic patients with cardiovascular diseases and its change during a single hemodialysis session. *Ren Fail*. 2017;39(1):719–28.
26. Basu R, Poglitsch M, Yogasundaram H, Thomas J, Rowe BH, Oudit GY. Roles of angiotensin peptides and recombinant human ACE2 in heart failure. *J Am Coll Cardiol*. 2017;69(7):805–19.
27. Bell K, Twiggs J, Olin BR. Hypertension: the silent killer: updated JNC-8 guideline recommendation. *Am Acad Fam Physicians*. 2015:1–8.
28. Mohani C I. Hipertensi primer. Dalam Buku Ajar Ilmu Penyakit Dalam. Volume II jilid VI. Jakarta. Interna publishing. 2014:2284-93.
29. Freeman AJ, Vinh A, Widdop RE. Novel approaches for treating hypertension. 2017;6: 1-8.
30. Beevers G, Lip GYH, Brien EO, No A. The pathophysiology of hypertension Gerardo Gamba Cardiac output and peripheral resistance Renin-angiotensin system Autonomic nervous system. 2001;322:912–6.

31. Majumder K, Wu J. Molecular targets of antihypertensive peptides: Understanding the mechanisms of action based on the pathophysiology of hypertension. *Int J Mol Sci.* 2014;16(1):256–83.
32. Ferrario CM. Interplay between ACE2 and angiotensin-(1-7) in the regulation of blood pressure. *Curr Hypertens Rev.* 2007;3(2):97–104.
33. Sandberg K, Ji H. Sex differences in primary hypertension. *Biol Sex Differ.* 2012;3(1):7.1-21.
34. Ferreira AJ, Bader M, Santos RA. Therapeutic targeting of the angiotensin-converting enzyme 2/Angiotensin-(1-7)/Mas cascade in the renin–angiotensin system: a patent review. *Expert Opin Ther Pat.* 2012;22(5):567–74.
35. Wysocki J, Gonzalez-Pacheco FR, Batlle D. Angiotensin-converting enzyme 2: possible role in hypertension and kidney disease. *Curr Hypertens Rep.* 2008;10(1):70–7.
36. Maranon R, Reckelhoff JF. Sex and gender differences in control of blood pressure. *Clin Sci.* 2013;125(7):311–8.
37. Mehta AR. Hypertension in elderly. *Clin Queries Nephrol.* 2013;2(3):96–102.
38. Oliva R V., Bakris GL. Management of hypertension in the elderly population. *Journals Gerontol Ser A Biol Sci Med Sci.* 2012;67(12):1343–51.
39. Barlassina C. Genetics of essential hypertension: from families to genes. *J Am Soc Nephrol.* 2002;13:155–164.
40. Gupte M, Thatcher SE, Boustany-Kari CM, Shoemaker R, Yiannikouris F, Zhang X, et al. Angiotensin converting enzyme 2 contributes to sex differences in the development of obesity hypertension in C57BL/6 mice. *Arterioscler Thromb Vasc Biol.* 2012;32(6):1392–9.
41. Yang HY, Lu KC, Fang WH, Lee HS, Wu CC, Huang YH, et al. Impact of interaction of cigarette smoking with angiotensin-converting enzyme



- polymorphisms on end-stage renal disease risk in a Han Chinese population. *Renin-Angiotensin-Aldosterone Syst.* 2015;16(1):203–10.
42. Virdis A, Giannarelli C, Neves MF, Taddei S, Ghiadoni L. Cigarette smoking and hypertension. *Curr Pharm Des.* 2010;16(23):2518–25.
  43. Fazizi F, Esmailzadeh A, Mirmiran FP. Obesity and cardiovascular disease risk factors in Tehran adults: a population-based study. *East Mediterr Health J.* 2004;10(6):887–97.
  44. Kotsis V, Stabouli S, Papakatsika S, Rizos Z, Parati G. Mechanisms of obesity-induced hypertension. *Hypertens Res.* 2010;33(5):386–93.
  45. Hall JE, Carmo JM, Silva AA, Wang Z, Hall ME. Hypertension compendium. 2015:991–1007.
  46. Schütten MTJ, Houben AJHM, de Leeuw PW, Stehouwer CDA. The link between adipose tissue renin-angiotensin-aldosterone system signaling and obesity-associated hypertension. *Physiology.* 2017;32(3):197–209.
  47. Rüter C, Wolf G. The Role of the Renin-Angiotensin-Aldosterone System in Obesity-Related Renal Diseases. *Semin Nephrol.* 2013;33(1):44–53.
  48. Ha SK. Dietary Salt Intake and Hypertension. *The Korean Society of Electrolyte Metabolism.* 2014;12:7-18.
  49. Kittana N. Angiotensin-converting enzyme 2–Angiotensin 1-7/1-9 system: novel promising targets for heart failure treatment. *Fundam Clin Pharmacol.* 2018;32(1):14–25.
  50. Wang Y, Tikellis C, Thomas MC, Golledge J. Angiotensin converting enzyme 2 and atherosclerosis. *Atherosclerosis.* 2013;226(1):3–8.
  51. Song B, Zhang Z-Z, Zhong J-C, Yu X-Y, Oudit GY, Jin H-Y, et al. Loss of Angiotensin-Converting Enzyme 2 Exacerbates Myocardial Injury via Activation of the CTGF-Fractalkine Signaling Pathway. *Circ J.* 2013;77(12):2997–3006.

52. Yang T, Xu C. Physiology and Pathophysiology of the Intrarenal Renin-Angiotensin System: An Update. *J Am Soc Nephrol*. 2017;28(4):1040–9.
53. Ferreira AJ, Murça TM, Fraga-Silva RA, Castro CH, Raizada MK, Santos RAS. New cardiovascular and pulmonary therapeutic strategies based on the angiotensin-converting enzyme 2/angiotensin-(1-7)/mas receptor axis. *Int J Hypertens*. 2012:1-13.
54. Susanto JP. Konsep baru renin angiotensin system ( RAS ). *Contin Prof Dev*. 2015;42(2):102–5.
55. Tikellis C, Thomas MC. Angiotensin-converting enzyme 2 (ACE2) is a key modulator of the renin angiotensin system in health and disease. *Int J Pept*. 2012:1-9.
56. Mizuiri S. ACE and ACE2 in kidney disease. *World J Nephrol*. 2015;4(1):74-82
57. Mendoza Torres E, Oyarzún A, Mondaca Ruff D, Azocar A, Chiong M, Castro PF, et al. ACE2 and vasoactive peptides: Novel players in cardiovascular/renal remodeling and hypertension. *Ther Adv Cardiovasc Dis*. 2015;9(4):217–37.
58. Oparil S, Schmieder RE. New Approaches in the treatment of hypertension. *Circ Res*. 2015;116(6):1074–95.
59. Siragy HM, Carey RM. Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease. *Am J Nephrol*. 2010;31(6):541–50.
60. Tikellis C, Bernardi S, Burns WC. Angiotensin-converting enzyme 2 is a key modulator of the renin-angiotensin system in cardiovascular and renal disease. *Curr Opin Nephrol Hypertens*. 2011;20(1):62–8.
61. Chappell MC. Does ACE2 contribute to the development of hypertension. *Hypertens Res*. 2010;33(2):107–9.
62. Sastroasmoro S, Ismael S. Dasar-dasar metodologi penelitian klinis. 5th ed. Sagung Seto; 2014: 376-377.
63. Uri K, Fagyas M, Siket IM, Kertész A, Csanádi Z, Sándorfi G, et al. New

- perspectives in the renin-angiotensin-aldosterone system (RAAS) IV: Circulating ACE2 as a biomarker of systolic dysfunction in human hypertension and heart failure. *PLoS One*. 2014;9(4): 1-13
64. Bargman JM, Skorecki K. Chronic kidney disease. In Harrison's principles of internal medicine.. Ed 19 . Editors by Kasper DL, Hauster SL, Jameson JL, Fauci AS, Longo DL, Loscalzo J. USA : Mc Graw-Hill. 2015:1811-14.
65. Panzer SE, Thurman JM. The patient with glomerular disease or vasculitis. In Manual of Nephrology. Ed 8. Editors by Schrier RW. USA: Wolters Kluwer Health. 2015:180-200.
66. Ghosh S, Mukhopadhyay S, Barik A. Sex differences in the risk profile of hypertension: A cross-sectional study. *BMJ Open*. 2016;6(7):1–8.
67. Akl C, Akik C, Ghattas H, Obermeyer CM. Gender disparities in midlife hypertension : a review of the evidence on the Arab region. 2017:1–10.
68. Choi HM, Kim HC, Kang DR. Sex differences in hypertension prevalence and control: Analysis of the 2010-2014 Korea national health and nutrition examination survey. *PLoS One*. 2017;12(5):1–12.
69. Yoon HE, Kim EN, Kim MY, Lim JH, Jang IA, Ban TH, et al. Age-Associated Changes in the Vascular Renin-Angiotensin System in Mice. *Oxid Med Cell Longev*. 2016;16(2):1-14
70. Uri K, Fagyas M, Kertesz A, Borbely A, Jenei C, Bene O, et al. Circulating ACE2 activity correlates with cardiovascular disease development. *J Renin Angiotensin Aldosterone Syst*. 2016;17(4): 1-11
71. Praso S, Jusupovic F, Ramic E, Gledo I, Ferkovic V, Novakovic B, et al. Obesity as a Risk Factor for Arterial Hypertension. *Mat Soc Med*. 2012;24(2):87–90.
72. Hammadeh ME, Sykoutris A, Schmidt W. Relationship Between Body Mass Index and Reproduction. *Curr Womens Health Rev*. 2005;1(2):131–42.

73. Taylor BC, Wilt TJ, Welch HG. Impact of diastolic and systolic blood pressure on mortality: Implications for the definition of “normal.” *J Gen Intern Med.* 2011;26(7):685–90.
74. Mungreiphy NK, Kapoor S, Sinha R. Association between BMI, blood pressure, and age: study among tangkhul naga tribal males of northeast India. *J Anthropol.*2011:1–6.
75. AL-Hamdan IH. Estimation of Serum Uric Acid, Urea and Creatinine in Essential Hypertensive Patients. *Tikrit Med J.* 2010;16(1):152–8.
76. Anguiano L, Riera M, Pascual J, Valdivielso JM, Barrios C, Betriu A, et al. Circulating angiotensin converting enzyme 2 activity as a biomarker of silent atherosclerosis in patients with chronic kidney disease. *Atherosclerosis.* 2016;253:135–43.
77. Gupte M, Thatcher SE, Boustany-Kari CM, Shoemaker R, Yiannikouris F, Zhang X, et al. Angiotensin converting enzyme 2 contributes to sex differences in the development of obesity hypertension in C57BL/6 mice. *Arterioscler Thromb Vasc Biol.* 2012;32(6):1392–9.
78. Patel SK, Velkoska E, Freeman M, Wai B, Lancefield TF, Burrell LM. From gene to protein-experimental and clinical studies of ACE2 in blood pressure control and arterial hypertension. *Front Physiol.* 2014:1–12.
79. Zhang Q, Cong M, Wang N, Li X, Zhang H, Zhang K, et al. Association of angiotensin-converting enzyme 2 gene polymorphism and enzymatic activity with essential hypertension in different gender. *Medicine (Baltimore)* 2018;97(42):1-17.
80. Epelman S, Tang WHW, Chen SY, Van Lente F, Francis GS, Sen S. Detection of Soluble Angiotensin-Converting Enzyme 2 in Heart Failure. Insights Into the Endogenous Counter-Regulatory Pathway of the Renin-Angiotensin-Aldosterone System. *J Am Coll Cardiol.* 2008;52(9):750–4.



81. Walker WG, Horvath JS, Moore MA, Whelton P, Russell RP. Relation between plasma renin activity, angiotensin, and aldosterone and blood pressure in mild untreated hypertension. *Circ Res.* 1976;38(6):470–6.
82. Song AL, Zeng ZP, Tong AL, Lu L, Chen S, Li M, Fu CL, Wang YH SM. Differences of blood plasma renin activity, angiotensin II and aldosterone levels in essential or secondary hypertension. *Zhonghua Nei Ke Za Zhi.* 2012;51(4):294–8.
83. Abu Arab TM, El Nozahi M, Wahid W, Hanna HF. Angiotensin II as an Indicator of Left ventricular Hypertrophy in Uncontrolled Treated Hypertensive Patients. *Int J Cardiovasc Res.* 2017;6(2):1–7.
84. Sylvestris A. Hipertensi dan retinopati hipertensi. *E-journal UMM.* 2014;10(1):1-9.
85. Giner V, Poch E, Bragulat E, Oriola J, González D, Coca A, et al. Renin-angiotensin system genetic polymorphisms and salt sensitivity in essential hypertension. *Hypertension.* 2000;35(2):512–7.
86. Keidar S, Strizevsky A, Raz A, Gamliel-Lazarovich A. ACE2 activity is increased in monocyte-derived macrophages from prehypertensive subjects. *Nephrol Dial Transplant.* 2007;22(2):597–601.
87. Gowrisankar Y V., Clark MA. Angiotensin II regulation of angiotensin-converting enzymes in spontaneously hypertensive rat primary astrocyte cultures. *J Neurochem.* 2016:74–85.